Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma

To investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally distinct tumors. We prospectively sequenced tumors and matched germline DNA using targeted next-generation sequencing methods. T...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 25; no. 3; pp. 967 - 976
Main Authors Audenet, François, Isharwal, Sumit, Cha, Eugene K., Donoghue, Mark T.A., Drill, Esther N., Ostrovnaya, Irina, Pietzak, Eugene J., Sfakianos, John P., Bagrodia, Aditya, Murugan, Paari, Dalbagni, Guido, Donahue, Timothy F., Rosenberg, Jonathan E., Bajorin, Dean F., Arcila, Maria E., Hechtman, Jaclyn F., Berger, Michael F., Taylor, Barry S., Al-Ahmadie, Hikmat, Iyer, Gopa, Bochner, Bernard H., Coleman, Jonathan A., Solit, David B.
Format Journal Article
LanguageEnglish
Published United States 01.02.2019
Subjects
Online AccessGet full text
ISSN1078-0432
1557-3265
1557-3265
DOI10.1158/1078-0432.CCR-18-2039

Cover

Abstract To investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally distinct tumors. We prospectively sequenced tumors and matched germline DNA using targeted next-generation sequencing methods. The cohort included 195 UTUC patients and 454 UCB patients. For a subgroup of 29 patients with UTUC and a history of a subsequent UCB, both tumors were analyzed to assess their clonal relatedness. With the progression to higher UTUC clinical state, there were fewer alterations in the RTK/RAS pathway but more alterations in TP53/MDM2. Compared with UCB, and were less frequently altered in UTUC (26% vs. 46%, 3% vs. 20%, 8% vs. 19%, respectively; < 0.001), whereas and were more frequently altered (40% vs. 26%, 12% vs. 4%, respectively; < 0.001). On the basis of an integrated analysis of tumor mutational burden, MSIsensor score and mutational signature, 7.2% of UTUC tumors were classified as MSI-high/MMR-deficient (MSI-H/dMMR). The risk of bladder recurrence after UTUC was significantly associated with mutations in and . Comparison of UCB with corresponding UTUC tumors from the same patient supports their clonal relatedness. UTUC and UCB exhibit significant differences in the prevalence of common genomic alterations. In individual patients with a history of both tumors, UCB and UTUC were always clonally related. Genomic characterization of UTUC provides information regarding the risk of bladder recurrence and can identify tumors associated with Lynch syndrome.
AbstractList To investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally distinct tumors. We prospectively sequenced tumors and matched germline DNA using targeted next-generation sequencing methods. The cohort included 195 UTUC patients and 454 UCB patients. For a subgroup of 29 patients with UTUC and a history of a subsequent UCB, both tumors were analyzed to assess their clonal relatedness. With the progression to higher UTUC clinical state, there were fewer alterations in the RTK/RAS pathway but more alterations in TP53/MDM2. Compared with UCB, and were less frequently altered in UTUC (26% vs. 46%, 3% vs. 20%, 8% vs. 19%, respectively; < 0.001), whereas and were more frequently altered (40% vs. 26%, 12% vs. 4%, respectively; < 0.001). On the basis of an integrated analysis of tumor mutational burden, MSIsensor score and mutational signature, 7.2% of UTUC tumors were classified as MSI-high/MMR-deficient (MSI-H/dMMR). The risk of bladder recurrence after UTUC was significantly associated with mutations in and . Comparison of UCB with corresponding UTUC tumors from the same patient supports their clonal relatedness. UTUC and UCB exhibit significant differences in the prevalence of common genomic alterations. In individual patients with a history of both tumors, UCB and UTUC were always clonally related. Genomic characterization of UTUC provides information regarding the risk of bladder recurrence and can identify tumors associated with Lynch syndrome.
To investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally distinct tumors.PURPOSETo investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally distinct tumors.We prospectively sequenced tumors and matched germline DNA using targeted next-generation sequencing methods. The cohort included 195 UTUC patients and 454 UCB patients. For a subgroup of 29 patients with UTUC and a history of a subsequent UCB, both tumors were analyzed to assess their clonal relatedness.EXPERIMENTAL DESIGNWe prospectively sequenced tumors and matched germline DNA using targeted next-generation sequencing methods. The cohort included 195 UTUC patients and 454 UCB patients. For a subgroup of 29 patients with UTUC and a history of a subsequent UCB, both tumors were analyzed to assess their clonal relatedness.With the progression to higher UTUC clinical state, there were fewer alterations in the RTK/RAS pathway but more alterations in TP53/MDM2. Compared with UCB, TP53, RB1, and ERBB2 were less frequently altered in UTUC (26% vs. 46%, 3% vs. 20%, 8% vs. 19%, respectively; Q < 0.001), whereas FGFR3 and HRAS were more frequently altered (40% vs. 26%, 12% vs. 4%, respectively; Q < 0.001). On the basis of an integrated analysis of tumor mutational burden, MSIsensor score and mutational signature, 7.2% of UTUC tumors were classified as MSI-high/MMR-deficient (MSI-H/dMMR). The risk of bladder recurrence after UTUC was significantly associated with mutations in FGFR3, KDM6A, CCND1, and TP53. Comparison of UCB with corresponding UTUC tumors from the same patient supports their clonal relatedness.RESULTSWith the progression to higher UTUC clinical state, there were fewer alterations in the RTK/RAS pathway but more alterations in TP53/MDM2. Compared with UCB, TP53, RB1, and ERBB2 were less frequently altered in UTUC (26% vs. 46%, 3% vs. 20%, 8% vs. 19%, respectively; Q < 0.001), whereas FGFR3 and HRAS were more frequently altered (40% vs. 26%, 12% vs. 4%, respectively; Q < 0.001). On the basis of an integrated analysis of tumor mutational burden, MSIsensor score and mutational signature, 7.2% of UTUC tumors were classified as MSI-high/MMR-deficient (MSI-H/dMMR). The risk of bladder recurrence after UTUC was significantly associated with mutations in FGFR3, KDM6A, CCND1, and TP53. Comparison of UCB with corresponding UTUC tumors from the same patient supports their clonal relatedness.UTUC and UCB exhibit significant differences in the prevalence of common genomic alterations. In individual patients with a history of both tumors, UCB and UTUC were always clonally related. Genomic characterization of UTUC provides information regarding the risk of bladder recurrence and can identify tumors associated with Lynch syndrome.CONCLUSIONSUTUC and UCB exhibit significant differences in the prevalence of common genomic alterations. In individual patients with a history of both tumors, UCB and UTUC were always clonally related. Genomic characterization of UTUC provides information regarding the risk of bladder recurrence and can identify tumors associated with Lynch syndrome.
Author Dalbagni, Guido
Ostrovnaya, Irina
Al-Ahmadie, Hikmat
Rosenberg, Jonathan E.
Cha, Eugene K.
Arcila, Maria E.
Drill, Esther N.
Iyer, Gopa
Pietzak, Eugene J.
Audenet, François
Donoghue, Mark T.A.
Taylor, Barry S.
Bochner, Bernard H.
Isharwal, Sumit
Bagrodia, Aditya
Sfakianos, John P.
Coleman, Jonathan A.
Solit, David B.
Berger, Michael F.
Murugan, Paari
Bajorin, Dean F.
Hechtman, Jaclyn F.
Donahue, Timothy F.
AuthorAffiliation 5 Department of Urology, UT Southwestern Medical Center, Dallas, USA
8 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
1 Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
2 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
7 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
6 Department of Laboratory Medicine and Pathology, University of Minnesota, USA
4 Department of Urology, Mount Sinai Hospital, New York, USA
9 Weil Cornell Medical College, New York, USA
3 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA
AuthorAffiliation_xml – name: 5 Department of Urology, UT Southwestern Medical Center, Dallas, USA
– name: 2 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
– name: 6 Department of Laboratory Medicine and Pathology, University of Minnesota, USA
– name: 3 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA
– name: 9 Weil Cornell Medical College, New York, USA
– name: 8 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
– name: 1 Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
– name: 4 Department of Urology, Mount Sinai Hospital, New York, USA
– name: 7 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
Author_xml – sequence: 1
  givenname: François
  orcidid: 0000-0001-5722-2075
  surname: Audenet
  fullname: Audenet, François
– sequence: 2
  givenname: Sumit
  surname: Isharwal
  fullname: Isharwal, Sumit
– sequence: 3
  givenname: Eugene K.
  surname: Cha
  fullname: Cha, Eugene K.
– sequence: 4
  givenname: Mark T.A.
  surname: Donoghue
  fullname: Donoghue, Mark T.A.
– sequence: 5
  givenname: Esther N.
  surname: Drill
  fullname: Drill, Esther N.
– sequence: 6
  givenname: Irina
  surname: Ostrovnaya
  fullname: Ostrovnaya, Irina
– sequence: 7
  givenname: Eugene J.
  surname: Pietzak
  fullname: Pietzak, Eugene J.
– sequence: 8
  givenname: John P.
  surname: Sfakianos
  fullname: Sfakianos, John P.
– sequence: 9
  givenname: Aditya
  surname: Bagrodia
  fullname: Bagrodia, Aditya
– sequence: 10
  givenname: Paari
  surname: Murugan
  fullname: Murugan, Paari
– sequence: 11
  givenname: Guido
  surname: Dalbagni
  fullname: Dalbagni, Guido
– sequence: 12
  givenname: Timothy F.
  surname: Donahue
  fullname: Donahue, Timothy F.
– sequence: 13
  givenname: Jonathan E.
  surname: Rosenberg
  fullname: Rosenberg, Jonathan E.
– sequence: 14
  givenname: Dean F.
  surname: Bajorin
  fullname: Bajorin, Dean F.
– sequence: 15
  givenname: Maria E.
  surname: Arcila
  fullname: Arcila, Maria E.
– sequence: 16
  givenname: Jaclyn F.
  surname: Hechtman
  fullname: Hechtman, Jaclyn F.
– sequence: 17
  givenname: Michael F.
  surname: Berger
  fullname: Berger, Michael F.
– sequence: 18
  givenname: Barry S.
  surname: Taylor
  fullname: Taylor, Barry S.
– sequence: 19
  givenname: Hikmat
  surname: Al-Ahmadie
  fullname: Al-Ahmadie, Hikmat
– sequence: 20
  givenname: Gopa
  surname: Iyer
  fullname: Iyer, Gopa
– sequence: 21
  givenname: Bernard H.
  surname: Bochner
  fullname: Bochner, Bernard H.
– sequence: 22
  givenname: Jonathan A.
  surname: Coleman
  fullname: Coleman, Jonathan A.
– sequence: 23
  givenname: David B.
  surname: Solit
  fullname: Solit, David B.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30352907$$D View this record in MEDLINE/PubMed
BookMark eNqFkV1rFDEUhoO02A_9CcpcejM1Jx-TDIKg4ye0FEr3OmQyZ2wkm6zJrOK_N9tti3pTCCTkPO85Ic8JOYgpIiEvgJ4BSP0aqNItFZydDcNVC7pllPdPyDFIqVrOOnlQz_fMETkp5TulIICKp-SIUy5ZT9UxGYeQog3NFQa74BSxlMbGqbnYLnbxt6UPfp4xY3RYmhGXX4ixWW02mJvrbN1yi78PdprqzSqn5QaDr7HBZudjWttn5HC2oeDzu_2UrD59vB6-tOeXn78O785bJ5Ra2k6im7VibkTXT-NMEeTcazEqTiUVruMTIK2LKaaB28oBoIaZia7TgvFT8nbfd7Md1zg5jEu2wWyyX9v82yTrzb-V6G_Mt_TTdFz2vYLa4NVdg5x-bLEsZu2LwxBsxLQthgGTHEDIvqIv_571MOT-Yysg94DLqZSM8wMC1OwEmp0cs5NjqkAD2uwE1tyb_3LO703UJ_vwSPoPv0eh_Q
CitedBy_id crossref_primary_10_3389_fonc_2021_766576
crossref_primary_10_3389_fruro_2023_1229709
crossref_primary_10_3390_curroncol31110511
crossref_primary_10_3390_cancers14143537
crossref_primary_10_1016_j_jasc_2020_06_011
crossref_primary_10_1111_bju_15735
crossref_primary_10_1177_15330338231159753
crossref_primary_10_3390_cancers13174341
crossref_primary_10_3390_ijms251910348
crossref_primary_10_1002_ijc_33327
crossref_primary_10_1002_cncr_32806
crossref_primary_10_1016_j_eururo_2020_05_039
crossref_primary_10_1080_2162402X_2022_2124691
crossref_primary_10_1097_MOU_0000000000000596
crossref_primary_10_1177_00369330221134233
crossref_primary_10_1007_s10689_022_00306_z
crossref_primary_10_1016_j_euf_2020_08_001
crossref_primary_10_1186_s12885_019_6227_7
crossref_primary_10_3390_cancers14194841
crossref_primary_10_1016_j_ajur_2021_06_005
crossref_primary_10_1016_j_bspc_2024_107431
crossref_primary_10_1158_2159_8290_CD_18_1196
crossref_primary_10_1038_s41588_024_02015_y
crossref_primary_10_1016_j_eururo_2023_03_013
crossref_primary_10_1097_MOU_0000000000000639
crossref_primary_10_1016_j_clgc_2019_07_011
crossref_primary_10_3390_biomedicines10092223
crossref_primary_10_1002_cam4_6112
crossref_primary_10_1002_path_6265
crossref_primary_10_1016_j_clgc_2022_06_013
crossref_primary_10_1002_cncr_32804
crossref_primary_10_1016_j_euo_2024_01_013
crossref_primary_10_3233_BLC_200282
crossref_primary_10_1016_j_urolonc_2020_01_014
crossref_primary_10_1172_JCI169241
crossref_primary_10_1159_000530710
crossref_primary_10_1038_s41467_024_46320_w
crossref_primary_10_3390_jcm10184197
crossref_primary_10_1002_advs_202103999
crossref_primary_10_23736_S2724_6051_24_05701_X
crossref_primary_10_1080_2090598X_2021_1883810
crossref_primary_10_1016_j_ctrv_2022_102351
crossref_primary_10_1093_jjco_hyab003
crossref_primary_10_1016_j_urology_2023_11_019
crossref_primary_10_1016_j_humpath_2021_09_007
crossref_primary_10_1038_s41598_023_30356_x
crossref_primary_10_3389_fimmu_2022_994594
crossref_primary_10_1007_s00795_021_00301_w
crossref_primary_10_1002_kjm2_12104
crossref_primary_10_1016_j_path_2024_08_004
crossref_primary_10_1055_s_0045_1805081
crossref_primary_10_1016_j_urology_2020_07_034
crossref_primary_10_1158_1078_0432_CCR_20_4419
crossref_primary_10_1016_j_urolonc_2020_01_008
crossref_primary_10_1111_cas_14782
crossref_primary_10_1016_j_ajur_2024_10_006
crossref_primary_10_1016_j_csbj_2021_08_037
crossref_primary_10_1097_MOU_0000000000000899
crossref_primary_10_3390_jcm11154483
crossref_primary_10_1016_j_clgc_2019_08_010
crossref_primary_10_1007_s10147_020_01785_9
crossref_primary_10_1172_jci_insight_144920
crossref_primary_10_1016_j_humpath_2022_06_006
crossref_primary_10_1111_iju_15257
crossref_primary_10_3390_ijms221910612
crossref_primary_10_1016_j_urolonc_2019_11_010
crossref_primary_10_3390_jpm11111147
crossref_primary_10_1101_mcs_a003848
crossref_primary_10_1155_2022_3373851
crossref_primary_10_52420_umj_23_4_104
crossref_primary_10_1158_1078_0432_CCR_24_1583
crossref_primary_10_1200_JCO_23_01659
crossref_primary_10_1038_s41467_020_15885_7
crossref_primary_10_1186_s12894_023_01387_3
crossref_primary_10_1038_s41585_022_00578_1
crossref_primary_10_1177_00369330231151800
crossref_primary_10_1097_CAD_0000000000001200
crossref_primary_10_1097_MOU_0000000000000782
crossref_primary_10_3390_diagnostics13051004
crossref_primary_10_1172_jci_insight_128728
crossref_primary_10_1016_j_urolonc_2021_08_019
crossref_primary_10_1097_MOU_0000000000000943
crossref_primary_10_1093_pcmedi_pbaa020
crossref_primary_10_2217_fon_2021_1629
crossref_primary_10_1016_j_modpat_2023_100300
crossref_primary_10_3389_fonc_2021_779918
crossref_primary_10_4111_icu_20230066
crossref_primary_10_2147_CMAR_S445529
crossref_primary_10_1016_j_euros_2023_01_004
crossref_primary_10_1038_s41416_021_01488_6
crossref_primary_10_3390_ijms23095154
crossref_primary_10_1007_s00066_020_01640_w
crossref_primary_10_3389_fonc_2023_1123776
crossref_primary_10_1016_j_eururo_2023_09_017
crossref_primary_10_12688_f1000research_26841_1
crossref_primary_10_1016_j_eururo_2024_10_024
crossref_primary_10_1038_s41419_022_04983_7
crossref_primary_10_1186_s13059_023_03026_4
crossref_primary_10_3390_genes12030333
crossref_primary_10_2217_imt_2021_0109
crossref_primary_10_1016_j_eururo_2020_04_021
crossref_primary_10_3390_jcm13216593
crossref_primary_10_1136_bmjonc_2024_000335
crossref_primary_10_1016_j_urolonc_2020_05_002
crossref_primary_10_1186_s13000_023_01405_w
crossref_primary_10_1097_PAS_0000000000002331
crossref_primary_10_3390_jcm9123866
crossref_primary_10_1016_j_semradonc_2022_10_001
crossref_primary_10_3390_biomedicines11071775
crossref_primary_10_3390_cancers12020439
crossref_primary_10_1016_j_urolonc_2023_07_007
crossref_primary_10_1007_s00345_023_04701_8
crossref_primary_10_1186_s13000_021_01109_z
crossref_primary_10_1038_s41585_023_00725_2
crossref_primary_10_3389_fonc_2022_1031774
crossref_primary_10_3390_curroncol29060312
crossref_primary_10_1016_j_eururo_2020_07_018
crossref_primary_10_1177_00369330221130763
crossref_primary_10_1038_s41585_019_0145_y
crossref_primary_10_1038_s41467_019_10873_y
crossref_primary_10_3390_cancers14071640
crossref_primary_10_3389_fonc_2021_731318
crossref_primary_10_1111_iju_14656
crossref_primary_10_1016_j_path_2024_09_003
crossref_primary_10_1002_onco_13839
crossref_primary_10_1016_j_euo_2021_11_001
crossref_primary_10_1016_S0140_6736_20_30519_5
crossref_primary_10_1016_j_clgc_2020_03_006
crossref_primary_10_1200_JCO_19_01395
crossref_primary_10_1016_j_urology_2020_06_108
crossref_primary_10_1111_bju_16405
crossref_primary_10_3390_cancers15072002
crossref_primary_10_1002_path_5306
crossref_primary_10_2196_15363
crossref_primary_10_1016_j_euo_2020_12_007
crossref_primary_10_1200_JCO_25_00179
crossref_primary_10_1186_s13059_020_02230_w
crossref_primary_10_3390_curroncol29020060
crossref_primary_10_1002_ijc_32737
crossref_primary_10_1097_MOU_0000000000001025
crossref_primary_10_1007_s10147_020_01650_9
crossref_primary_10_1016_j_eururo_2024_12_006
crossref_primary_10_1097_PAS_0000000000002279
crossref_primary_10_1002_cam4_70398
crossref_primary_10_3390_cancers15092414
crossref_primary_10_1093_jjco_hyad172
crossref_primary_10_3389_fimmu_2022_1097730
crossref_primary_10_3390_biomedicines12092154
crossref_primary_10_3390_cancers13061448
crossref_primary_10_1016_j_ccell_2021_05_004
crossref_primary_10_1016_j_euo_2021_01_009
crossref_primary_10_2217_imt_2023_0028
crossref_primary_10_1016_j_ccell_2021_05_008
crossref_primary_10_4103_UROS_UROS_58_22
crossref_primary_10_1007_s00345_023_04700_9
crossref_primary_10_1111_bju_15324
crossref_primary_10_1111_bju_15566
crossref_primary_10_1158_2159_8290_CD_22_1441
crossref_primary_10_3390_cancers15020506
crossref_primary_10_3389_fpubh_2022_994351
crossref_primary_10_1002_cam4_6175
crossref_primary_10_1016_j_urolonc_2021_05_037
crossref_primary_10_1093_oncolo_oyad070
crossref_primary_10_1136_jitc_2024_010964
crossref_primary_10_3389_fonc_2022_990023
Cites_doi 10.1016/j.eururo.2014.11.035
10.1200/JCO.2018.36.6_suppl.411
10.1158/1078-0432.CCR-05-0891
10.1371/journal.pone.0038863
10.1093/bioinformatics/btt755
10.1038/nature12477
10.1016/j.eururo.2017.07.036
10.1093/nar/gkw520
10.1200/JCO.2017.35.15_suppl.4511
10.1093/aje/153.5.411
10.1073/pnas.0701248104
10.1016/j.jmoldx.2014.12.006
10.1111/j.1464-410X.2012.11298.x
10.3322/caac.21442
10.1016/j.eururo.2017.05.048
10.1016/j.cell.2017.09.007
10.1200/JCO.2012.46.5740
10.1016/j.eururo.2011.05.064
10.1038/nature12965
10.1016/j.juro.2012.05.079
10.1016/S0140-6736(16)00561-4
10.1038/nm.4333
10.1001/jamaoncol.2018.0104
10.1093/jnci/djs351
10.1038/s41568-018-0043-2
10.4238/2014.February.20.12
10.1111/j.1464-410X.2009.08838.x
10.1016/j.celrep.2012.12.008
10.1016/S0022-5347(05)67019-X
10.1016/j.eururo.2015.07.039
10.1016/j.eururo.2016.05.041
10.1016/j.eururo.2008.08.008
10.1214/15-AOAS836
10.1038/sj.onc.1210934
10.1186/2193-1801-2-412
10.1038/sj.onc.1204671
10.1016/0140-6736(93)92066-3
ContentType Journal Article
Copyright 2018 American Association for Cancer Research.
Copyright_xml – notice: 2018 American Association for Cancer Research.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1158/1078-0432.CCR-18-2039
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 976
ExternalDocumentID PMC6359971
30352907
10_1158_1078_0432_CCR_18_2039
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P30 CA008748
– fundername: NCI NIH HHS
  grantid: R01 CA182587
GroupedDBID ---
18M
29B
2FS
2WC
34G
39C
53G
5GY
5RE
5VS
6J9
AAFWJ
AAJMC
AAYXX
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
AFUMD
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BR6
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
H13
IH2
KQ8
L7B
LSO
OK1
P0W
P2P
QTD
RCR
RHI
RNS
SJN
TR2
W2D
W8F
WOQ
YKV
CGR
CUY
CVF
ECM
EIF
NPM
RHF
7X8
5PM
ID FETCH-LOGICAL-c477t-65ecf872cbec9dbf0e15f984b730504c63d1e01e0272813acbe11e81f24668423
ISSN 1078-0432
1557-3265
IngestDate Thu Aug 21 18:11:13 EDT 2025
Fri Sep 05 03:05:41 EDT 2025
Wed Feb 19 02:30:38 EST 2025
Thu Apr 24 22:52:24 EDT 2025
Tue Jul 01 01:30:20 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License 2018 American Association for Cancer Research.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c477t-65ecf872cbec9dbf0e15f984b730504c63d1e01e0272813acbe11e81f24668423
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-5722-2075
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/6359971
PMID 30352907
PQID 2125311459
PQPubID 23479
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6359971
proquest_miscellaneous_2125311459
pubmed_primary_30352907
crossref_primary_10_1158_1078_0432_CCR_18_2039
crossref_citationtrail_10_1158_1078_0432_CCR_18_2039
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-02-01
PublicationDateYYYYMMDD 2019-02-01
PublicationDate_xml – month: 02
  year: 2019
  text: 2019-02-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2019
References Colin (2022061019361331500_bib7) 2009; 104
The Cancer Genome Atlas Research Network (2022061019361331500_bib9) 2014; 507
O'Brien (2022061019361331500_bib34) 2011; 60
Wang (2022061019361331500_bib38) 2013; 2
Robertson (2022061019361331500_bib10) 2017; 171
Zehir (2022061019361331500_bib14) 2017; 23
Seisen (2022061019361331500_bib24) 2015; 67
Hurst (2022061019361331500_bib27) 2008; 27
Hafner (2022061019361331500_bib37) 2001; 20
Rouprêt (2022061019361331500_bib20) 2008; 54
Lindgren (2022061019361331500_bib26) 2012; 7
Win (2022061019361331500_bib8) 2012; 104
Ostrovnaya (2022061019361331500_bib17) 2015; 9
Loriot (2022061019361331500_bib29) 2018; 36
Moss (2022061019361331500_bib12) 2017; 72
Hampel (2022061019361331500_bib31) 2018; 4
Sfakianos (2022061019361331500_bib11) 2015; 68
Babjuk (2022061019361331500_bib2) 2017; 71
Green (2022061019361331500_bib4) 2013; 189
Grollman (2022061019361331500_bib6) 2007; 104
Cheng (2022061019361331500_bib28) 2018; 18
Jones (2022061019361331500_bib36) 2005; 11
Chiou (2022061019361331500_bib5) 2001; 153
Alexandrov (2022061019361331500_bib22) 2013; 500
Rosenberg (2022061019361331500_bib32) 2016; 387
Munoz (2022061019361331500_bib3) 2000; 164
Shen (2022061019361331500_bib15) 2016; 44
Liu (2022061019361331500_bib25) 2014; 13
Habuchi (2022061019361331500_bib35) 1993; 342
Iyer (2022061019361331500_bib18) 2013; 31
Rouprêt (2022061019361331500_bib21) 2018; 73
Audenet (2022061019361331500_bib30) 2012; 110
Siegel (2022061019361331500_bib1) 2018; 68
Alexandrov (2022061019361331500_bib23) 2013; 3
Middha (2022061019361331500_bib19) 2017
Cheng (2022061019361331500_bib13) 2015; 17
Iyer (2022061019361331500_bib33) 2017; 35
Niu (2022061019361331500_bib16) 2014; 30
31184534 - J Urol. 2019 Sep;202(3):456-457
References_xml – volume: 67
  start-page: 1122
  year: 2015
  ident: 2022061019361331500_bib24
  article-title: A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2014.11.035
– volume: 36
  start-page: 411
  year: 2018
  ident: 2022061019361331500_bib29
  article-title: Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.36.6_suppl.411
– volume: 11
  start-page: 6512
  year: 2005
  ident: 2022061019361331500_bib36
  article-title: Molecular evidence supporting field effect in urothelial carcinogenesis
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-0891
– volume: 7
  start-page: e38863
  year: 2012
  ident: 2022061019361331500_bib26
  article-title: Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0038863
– volume: 30
  start-page: 1015
  year: 2014
  ident: 2022061019361331500_bib16
  article-title: MSIsensor: microsatellite instability detection using paired tumor–normal sequence data
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btt755
– volume: 500
  start-page: 415
  year: 2013
  ident: 2022061019361331500_bib22
  article-title: Signatures of mutational processes in human cancer
  publication-title: Nature
  doi: 10.1038/nature12477
– volume: 73
  start-page: 111
  year: 2018
  ident: 2022061019361331500_bib21
  article-title: European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2017.07.036
– volume: 44
  start-page: e131
  year: 2016
  ident: 2022061019361331500_bib15
  article-title: FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkw520
– volume: 35
  start-page: 4511
  year: 2017
  ident: 2022061019361331500_bib33
  article-title: Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.35.15_suppl.4511
– volume: 153
  start-page: 411
  year: 2001
  ident: 2022061019361331500_bib5
  article-title: Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/153.5.411
– volume: 104
  start-page: 12129
  year: 2007
  ident: 2022061019361331500_bib6
  article-title: Aristolochic acid and the etiology of endemic (Balkan) nephropathy
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0701248104
– volume: 17
  start-page: 251
  year: 2015
  ident: 2022061019361331500_bib13
  article-title: Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology
  publication-title: J Mol Diagn
  doi: 10.1016/j.jmoldx.2014.12.006
– volume: 110
  start-page: E583
  year: 2012
  ident: 2022061019361331500_bib30
  article-title: A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2012.11298.x
– volume: 68
  start-page: 7
  year: 2018
  ident: 2022061019361331500_bib1
  article-title: Cancer statistics, 2018
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21442
– volume: 72
  start-page: 641
  year: 2017
  ident: 2022061019361331500_bib12
  article-title: Comprehensive genomic characterization of upper tract urothelial carcinoma
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2017.05.048
– volume: 171
  start-page: 540
  year: 2017
  ident: 2022061019361331500_bib10
  article-title: Comprehensive molecular characterization of muscle-invasive bladder cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2017.09.007
– volume: 31
  start-page: 3133
  year: 2013
  ident: 2022061019361331500_bib18
  article-title: Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.46.5740
– volume: 60
  start-page: 703
  year: 2011
  ident: 2022061019361331500_bib34
  article-title: Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial)
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2011.05.064
– volume: 507
  start-page: 315
  year: 2014
  ident: 2022061019361331500_bib9
  article-title: Comprehensive molecular characterization of urothelial bladder carcinoma
  publication-title: Nature
  doi: 10.1038/nature12965
– volume: 189
  start-page: 1214
  year: 2013
  ident: 2022061019361331500_bib4
  article-title: Urothelial carcinoma of the bladder and the upper tract: disparate twins
  publication-title: J Urol
  doi: 10.1016/j.juro.2012.05.079
– volume: 387
  start-page: 1909
  year: 2016
  ident: 2022061019361331500_bib32
  article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)00561-4
– volume: 23
  start-page: 703
  year: 2017
  ident: 2022061019361331500_bib14
  article-title: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
  publication-title: Nat Med
  doi: 10.1038/nm.4333
– volume: 4
  start-page: 806
  year: 2018
  ident: 2022061019361331500_bib31
  article-title: Assessment of tumor sequencing as a replacement for lynch syndrome screening and current molecular tests for patients with colorectal cancer
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2018.0104
– volume: 104
  start-page: 1363
  year: 2012
  ident: 2022061019361331500_bib8
  article-title: Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djs351
– volume: 18
  start-page: 527
  year: 2018
  ident: 2022061019361331500_bib28
  article-title: Clinical tumour sequencing for precision oncology: time for a universal strategy
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-018-0043-2
– volume: 13
  start-page: 1109
  year: 2014
  ident: 2022061019361331500_bib25
  article-title: Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis
  publication-title: Genet Mol Res
  doi: 10.4238/2014.February.20.12
– volume: 104
  start-page: 1436
  year: 2009
  ident: 2022061019361331500_bib7
  article-title: Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2009.08838.x
– volume: 3
  start-page: 246
  year: 2013
  ident: 2022061019361331500_bib23
  article-title: Deciphering signatures of mutational processes operative in human cancer
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2012.12.008
– volume: 164
  start-page: 1523
  year: 2000
  ident: 2022061019361331500_bib3
  article-title: Upper tract urothelial neoplasms: incidence and survival during the last 2 decades
  publication-title: J Urol
  doi: 10.1016/S0022-5347(05)67019-X
– volume: 68
  start-page: 970
  year: 2015
  ident: 2022061019361331500_bib11
  article-title: Genomic characterization of upper tract urothelial carcinoma
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2015.07.039
– volume: 71
  start-page: 447
  year: 2017
  ident: 2022061019361331500_bib2
  article-title: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2016.05.041
– volume: 54
  start-page: 1226
  year: 2008
  ident: 2022061019361331500_bib20
  article-title: Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2008.08.008
– volume: 9
  start-page: 1533
  year: 2015
  ident: 2022061019361331500_bib17
  article-title: Using somatic mutation data to test tumors for clonal relatedness
  publication-title: Ann Appl Stat
  doi: 10.1214/15-AOAS836
– volume: 27
  start-page: 2716
  year: 2008
  ident: 2022061019361331500_bib27
  article-title: Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210934
– volume: 2
  start-page: 412
  year: 2013
  ident: 2022061019361331500_bib38
  article-title: Comparison of the clonality of urothelial carcinoma developing in the upper urinary tract and those developing in the bladder
  publication-title: Springerplus
  doi: 10.1186/2193-1801-2-412
– start-page: 1
  year: 2017
  ident: 2022061019361331500_bib19
  article-title: Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data
  publication-title: JCO Precis Oncol
– volume: 20
  start-page: 4910
  year: 2001
  ident: 2022061019361331500_bib37
  article-title: Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1204671
– volume: 342
  start-page: 1087
  year: 1993
  ident: 2022061019361331500_bib35
  article-title: Metachronous multifocal development of urothelial cancers by intraluminal seeding
  publication-title: Lancet
  doi: 10.1016/0140-6736(93)92066-3
– reference: 31184534 - J Urol. 2019 Sep;202(3):456-457
SSID ssj0014104
Score 2.6398034
Snippet To investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 967
SubjectTerms Aged
Biomarkers, Tumor - genetics
Carcinoma, Transitional Cell - genetics
Clone Cells - metabolism
Colorectal Neoplasms, Hereditary Nonpolyposis - genetics
Female
Genetic Predisposition to Disease - genetics
Genomics - methods
High-Throughput Nucleotide Sequencing - methods
Humans
Male
Middle Aged
Mutation
Prospective Studies
Receptor, Fibroblast Growth Factor, Type 3 - genetics
Tumor Suppressor Protein p53 - genetics
Urinary Bladder - metabolism
Urinary Bladder - pathology
Urinary Bladder Neoplasms - genetics
Urinary Tract - metabolism
Urinary Tract - pathology
Title Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/30352907
https://www.proquest.com/docview/2125311459
https://pubmed.ncbi.nlm.nih.gov/PMC6359971
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdbB2MvY9_rvtBgb8GZZUuR9di5Kd3WdjASyJuILYUGMie4CYX-9buTZDtZA-sGwQRFthzdT6fTfRLyaar4DHYNGwllBhHncNyZKmUjVjBZFgZ2LIMHxfOLwemYf5uISWcucNEl66Jf3uyNK_kfqkIb0BWjZP-Bsu1DoQG-A33hChSG651onC-cHs85tFnjmJbzm9isGxXfcah_gn5XjUvWeLWyNWY1L713-ZcFcp-6N64xGmuBKvQcKwxVy8Czm0QGTRBliUipeyFPUKtPPsIsmd62geKwM8HL5fyqQ9_ltL52BQaAX_2atw43uTc6DTfwR22ndz1eVlhP2DYhRb1RULwGJQXGRbUOH4GvCuBliS8L0bd72gIz9lHQAXTpFmdVvmrHbY4vMqd8wETBPE36ef4zYggTnyNpN8P2xQ99Mj4706PhZHSfPEgkyFsoSH_93lqeOHMlJ9uXC1FfMMznvYPsyjO3Dil_-tpuCS-jJ-RxOHXQIw-hp-SerZ6Rh-fBr-I5KTyS6BaSKECDdkiiW0iiAUnUIYk6JLnuAUm0QxJtkfSCjE-Go_w0CtU3opJLuY4GwpazTCYlrHJlillsmZipjBewJ4iYl4PUMBvDJ5FJxtIp9GPMZgyW_gCNu-lLclAtK_ua0DK2wsjYFMD-uShEoYzBOgGZUXEyS-Qh4c0c6jKkpscKKQvtjqgi0zj1Gqdew9Rrlmmc-kPSb29b-dwsf7vhY0MgDVwUTWPTyi43VxoEONiMGBfQ55UnWPvIFFMGqxjeUu6Qsu2AGdp3f6nmly5TO0jzSkn25g7jviWPuoXzjhys6419D_LuuvjgAPobRCyovw
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clonal+Relatedness+and+Mutational+Differences+between+Upper+Tract+and+Bladder+Urothelial+Carcinoma&rft.jtitle=Clinical+cancer+research&rft.au=Audenet%2C+Fran%C3%A7ois&rft.au=Isharwal%2C+Sumit&rft.au=Cha%2C+Eugene+K&rft.au=Donoghue%2C+Mark+T+A&rft.date=2019-02-01&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=25&rft.issue=3&rft.spage=967&rft_id=info:doi/10.1158%2F1078-0432.CCR-18-2039&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon